Observational study of blood clotting and bleeding disorders in Chinese patients
Longitudinal Cohort of Thrombosis and Hemostasis Diseases
Peking University People's Hospital · NCT06727669
This study looks at blood clotting and bleeding problems in Chinese patients to see how common they are and what factors might affect them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Sex | All |
| Sponsor | Peking University People's Hospital (other) |
| Locations | 5 sites (Beijing, Beijing Municipality and 4 other locations) |
| Trial ID | NCT06727669 on ClinicalTrials.gov |
What this trial studies
This multicenter, prospective, longitudinal observational cohort study aims to investigate thrombosis and hemostasis diseases among Chinese patients. It will collect comprehensive data on patient demographics, diagnostic and treatment information, and medical expenses from medical records. The study will analyze the incidence and risk factors associated with these diseases, as well as treatment methods and patient prognosis through follow-up questionnaires. By focusing on a large-scale cohort, this study seeks to fill the gaps left by previous smaller studies.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with thrombosis and hemostasis diseases.
Not a fit: Patients who have serious concomitant diseases or those unable to comply with study requirements may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of thrombosis and hemostasis diseases, enhancing patient outcomes.
How similar studies have performed: While there have been smaller studies on these conditions, this large-scale, comprehensive approach is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who were diagnosed as thrombosis and hemostasis diseases. Exclusion Criteria: * Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease. * Patients with alcohol and drug addictions or mental illness affect their ability to comply with study requirements. * According to the investigator, there are conditions that may endanger the patient's safety or affect his/her compliance.
Where this trial is running
Beijing, Beijing Municipality and 4 other locations
- Peking University Insititute of Hematology, Peking University People's Hospital — Beijing, Beijing Municipality, China (RECRUITING)
- Department of Hematology, Beijing Friendship Hospital, Capital Medical University — Beijing, Beijing Municipality, China (NOT_YET_RECRUITING)
- Department of Hematology, Beijing Hospital — Beijing, Beijing Municipality, China (NOT_YET_RECRUITING)
- The First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan, China (NOT_YET_RECRUITING)
- Xinqiao Hospital, Army Military Medical University — Chongqing, China (NOT_YET_RECRUITING)
Study contacts
- Principal investigator: Xiao-Hui Zhang, MD — Peking University Institute of Hematology, Peking University People's Hospital
- Study coordinator: Haixia Fu, MD
- Email: fuhaixia_210@163.com
- Phone: 086-01088326002
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura, Hemophilia A, Acquired, Disseminated Intravascular Coagulation, Thrombophilia, Deep Vein Thrombosis, Pulmonary Embolism, Thrombotic Microangiopathies